Advertisement
U.S. markets open in 8 hours 14 minutes

Ayala Pharmaceuticals, Inc. (ADXS)

Other OTC - Other OTC Delayed Price. Currency in USD
0.5974-0.0226 (-3.65%)
At close: 11:27AM EDT

Ayala Pharmaceuticals, Inc.

1007 North Orange Street
4th Floor
Wilmington, DE 19802
United States
857-444-0553
https://www.ayalapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Ruth Ben Yakar Ph.D.Chief Exec. OfficerN/AN/A1970
Dr. Stela Gangrenovitch Ph.D.Co-Founder, Chief Scientist Officer and DirectorN/AN/AN/A
Mr. Mark Gengrinovitch LLBCo-Founder, Chief Financial Officer and DirectorN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Corporate Governance

Ayala Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.